Cytodyn Inc (CYDY)

[tonecee]

March 2016 article:

https://www.poz.com/article/charlie-sheen-pining-wrong-clinical-trial-longacting-hiv-meds

"Flexner, who is also a professor of medicine at Johns Hopkins, says that a drawback of PRO 140 is its dosing frequency. While a weekly self-injectable may appeal to some people with HIV, the dominant focus in the mainstream long-acting HIV treatment research field today is on therapy that, while requiring a clinic visit for injections, is given only every eight weeks. The sole current player in this field is the long-acting injectable antiretroviral cocktail of ViiV Healthcare’s investigational integrase inhibitor cabotegravir and Janssen’s non-nucleoside reverse transcriptase inhibitor Edurant (rilpivirine)."